Clinical Pharmacokinetics of Anti-Parkinsonian Drugs

The Pharmacological Basis of Therapeutics

1976 • 8,675 citations

Recent developments in Parkinson's disease

1986 • 2,266 citations

Verteilung Von Noradrenalin Und Dopamin (3-Hydroxytyramin) Im Gehirn Des Menschen Und Ihr Verhalten Bei Erkrankungen Des Extrapyramidalen Systems

1960 • 1,863 citations

Aromatic Amino Acids and Modification of Parkinsonism

1967 • 1,464 citations

3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists

1957 • 1,233 citations

Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)

1985 • 620 citations

Treatment of Parkinsonism With Levodopa

1969 • 602 citations

Amantadine in the Treatment of Parkinson's Disease

1969 • 599 citations

SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASE

1977 • 585 citations

The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil

1975 • 361 citations

KINETICS OF COMPETITIVE INHIBITION OF NEUTRAL AMINO ACID TRANSPORT ACROSS THE BLOOD‐BRAIN BARRIER

1977 • 357 citations

Pharmacokinetics of Levodopa

1984 • 347 citations

Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.

1986 • 345 citations

Cholinergic-Anticholinergic Antagonism in Parkinsonism

1967 • 337 citations

Occurrence and distribution of catechol amines in brain.

1959 • 323 citations

Dopamine is a monoamine oxidase B substrate in man

1977 • 313 citations

Kinetic analysis of blood-brain barrier transport of amino acids

1975 • 306 citations

Deprenyl is metabolized to methamphetamine and amphetamine in man.

1978 • 287 citations

Fluctuations of disability in Parkinson's disease – clinical aspects

1981 • 281 citations

ON-OFF FLUCTUATIONS IN PARKINSON'S DISEASE

1984 • 276 citations

On‐off response

1975 • 273 citations

“On‐off” phenomenon with levodopa therapy in parkinsonism

1974 • 232 citations

L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.

1971 • 232 citations

Control of on/off phenomenon by continuous intravenous infusion of levodopa

1984 • 226 citations

High dosage anticholinergic therapy in dystonia

1983 • 217 citations

SYNTHETIC AMINO ACIDS AND THE NATURE OF <scp>l</scp>‐DOPA TRANSPORT AT THE BLOOD‐BRAIN BARRIER

1975 • 210 citations

The possible mechanisms of action of (-)deprenyl in Parkinson's disease

1978 • 207 citations

Cerebral accumulation and metabolism of C14-dopa after selective inhibition of peripheral decarboxylase.

1968 • 198 citations

Lisuride and Other Dopamine Agonists

1983 • 198 citations

Treatment of Parkinson's Syndrome with L Dihydroxyphenylalanine (Levodopa)

1970 • 184 citations

Serum Levels of Anticholinergic Drugs in Treatment of Acute Extrapyramidal Side Effects

1980 • 178 citations

Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease

1987 • 173 citations

Absorption, distribution and excretion of amantadine hydrochloride.

1965 • 164 citations

Inhibition of <scp>L</scp>‐{¹⁸F}fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography

1986 • 163 citations

The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: The mechanism of action in the treatment of parkinsonism

1985 • 157 citations

Active Transport of L-Dopa in the Intestine

1973 • 157 citations

Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients

1986 • 149 citations

Duodenal delivery of levodopa for on‐off fluctuations in parkinsonism: Preliminary observations

1986 • 140 citations

3-0-Methyldopa uptake and inhibition of L-dopa at the blood-brain barrier

1975 • 140 citations

Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease.

1977 • 138 citations

Protein Intake and Treatment of Parkinson's Disease with Levodopa

1975 • 136 citations

The metabolism of orally administered <scp>l</scp>‐DOPA in Parkinsonism

1969 • 135 citations

COMPLICATED RESPONSE FLUCTUATIONS IN PARKINSON'S DISEASE: RESPONSE TO INTRAVENOUS INFUSION OF LEVODOPA

1982 • 131 citations

Interaction of pergolide with central dopaminergic receptors.

1980 • 126 citations

Dyskinesia. Research and treatment.

1985 • 126 citations

Metabolic Modification of Parkinson's Disease and of Chronic Manganese Poisoning

1971 • 118 citations

Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients

1987 • 118 citations

Catechol-O-methyltransferase activity: A determinant of levodopa response

1980 • 114 citations

Patterns of clinical response and plasma dopa levels in Parkinson's disease

1975 • 111 citations

Pharmacokinetics of Amantadine Hydrochloride in Subjects with Normal and Impaired Renal Function

1981 • 109 citations

Intestinal Absorption of Essential Amino Acids in Man

1967 • 108 citations

Early-Morning Dystonia

1979 • 106 citations

Metabolic fate of L-[14C] DOPA in cerebrospinal fluid and blood plasma of humans

1967 • 101 citations

Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine

1985 • 99 citations

Pharmacokinetics of Diphenhydramine and a Demethylated Metabolite Following Intravenous And Oral Administration

1986 • 97 citations

The clinical physiology of side effects in long-term L-DOPA therapy.

1974 • 96 citations

Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.

1980 • 92 citations

Episodic unresponsiveness to single doses of L‐dopa in parkinsonian fluctuators

1986 • 91 citations

L-dopa treatment failure: explanation and correction.

1970 • 91 citations

Onset and End-of-Dose Levodopa-Induced Dyskinesias

1978 • 90 citations

Pharmacologic Effects in Man of a Potent, Long-Acting Dopamine Receptor Agonist

1979 • 86 citations

Methods in biogenic amine research

1983 • 85 citations

The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on‐off fluctuations.

1986 • 84 citations

The clinical phenomenon of akathisia.

1986 • 80 citations

METABOLISM AND ABSORPTION OF <scp>l</scp>‐3,4 DIHYDROXYPHENYLALANINE IN PATIENTS WITH PARKINSON'S DISEASE

1971 • 80 citations

Pharmacokinetics of diphenhydramine in man

1975 • 79 citations

Ergot compounds and brain function : neuroendocrine and neuropsychiatric aspects

1980 • 79 citations

Brain Catecholamines and Their Metabolites in Parkinsonian Patients

1973 • 75 citations

Enzymes Related to Monoamine Transmitter Metabolism in Brain Microvessels

1980 • 75 citations

L-deprenyl treatment of on-off phenomena in Parkinson's disease

1978 • 74 citations

AMANTADINE DOSAGE IN TREATMENT OF PARKINSON'S DISEASE

1970 • 74 citations

Plasma dopa concentrations and the “on‐off” effect after chronic treatment of Parkinson's disease

1974 • 72 citations

Diphenhydramine in Orientals and Caucasians

1980 • 72 citations

Pyridoxine reversal of L-dopa effects in Parkinsonism.

1969 • 70 citations

Drug-Induced Changes of Extracerebral Dopa Metabolism in Man

1969 • 68 citations

Absorption and Metabolism of Levodopa

1971 • 68 citations

Metabolism of 3,4-dihydroxyphenylalanine (l-DOPA) in human subjects

1972 • 66 citations

Controlled‐release levodopa/carbidopa.

1987 • 66 citations

The Clinical Picture and Plasma Levodopa Metabolite Profile of Parkinsonian Nonresponders

1977 • 64 citations

3-Methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease

1972 • 64 citations

The metabolism of L‐3–0‐methyldopa, aprecursor of dopa in man

1971 • 63 citations

Treatment of Motor Fluctuations in Parkinsonʼs Disease with an Oral Sustained-Release Preparation of L-Dopa

1986 • 62 citations

Long‐term evaluation of amantadine and levodopa combination in parkinsonism by double‐blind crossover analyses

1975 • 60 citations

Lisuride in parkinsonism

1981 • 60 citations

Clinical and biochemical studies with controlled‐release levodopa/carbidopa

1986 • 60 citations

DOPAMINE FORMATION IN BRAIN CAPILLARIES—AN ENZYMIC BLOOD–BRAIN BARRIER MECHANISM

1967 • 59 citations

Levodopa with benserazide or carbidopa in Parkinson disease

1979 • 59 citations

Systemic availability of orally administered L-dopa in the elderly Parkinsonian patient

1980 • 57 citations

Amantadine kinetics in healthy young subjects after long‐term dosing

1979 • 56 citations

TOXIC EFFECTS OF AMANTADINE IN PATIENTS WITH RENAL FAILURE

1979 • 55 citations

Intravenous lisuride corrects oscillations of motor performance in Parkinson's disease

1986 • 55 citations

Variability of L-Dopa Absorption in Man

1974 • 54 citations

Metabolic disposition of diphenhydramine

1974 • 53 citations

Neurochemical effects of some ergot derivatives: A basis for their antiparkinson actions

1981 • 50 citations

Amantadine kinetics in healthy elderly men: Implications for influenza prevention

1985 • 50 citations

Dopamine metabolism in the central nervous system after discontinuation of l-dopa therapy in patients with Parkinson disease

1984 • 49 citations

Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects

1986 • 49 citations

Pharmacokinetics and pharmacodynamics of procyclidine in man

1985 • 49 citations

Biopharmaceutical aspects of FK-506.

1987 • 49 citations

Anticholinergic and membrane activities of amantadine in neuromuscular transmission

1976 • 48 citations

Transamination is a Major Pathway of L-Dopa Metabolism following Peripheral Decarboxylase Inhibition

1974 • 48 citations

Levodopa in Parkinsonism: the Effects of Withdrawal of Anticholinergic Drugs

1971 • 48 citations

Treatment of Parkinson's disease: Problems with a progressing disease

1981 • 48 citations

Difference between single and multiple dose pharmacokinetics of orphenadrine hydrochloride in man

1982 • 47 citations

Experiences with L-deprenyl in Parkinsonism

1978 • 46 citations

Pergolide, a potent long-acting dopamine-receptor agonist

1980 • 45 citations

Diet and Uptake of Aldomet by the Brain: Competition with Natural Large Neutral Amino Acids

1977 • 44 citations

Dosage form Design for Improvement of Bioavailability of Levodopa II: Bioavailability of Marketed Levodopa Preparations in Dogs and Parkinsonian Patients

1980 • 44 citations

Effect of amantadine on drug‐induced parkisonism: relationship between plasma levels and effect.

1976 • 44 citations

Repeated Levodopa Infusions in Fluctuating Parkinsonʼs Disease

1986 • 43 citations

Amantadine Hydrochloride Pharmacokinetics in Hemodialysis Patients

1980 • 43 citations

The pharmacokinetics of bromocriptine in man.

1980 • 43 citations

Metabolism of Levodopa in Patients With Parkinson's Disease

1971 • 43 citations

Decrease in Liver Aromatic L-Amino-Acid Decarboxylase Produced by Chronic Administration of L-Dopa

1971 • 43 citations

Plasma DOPA response to levodopa administration in man: Effects of a peripheral decarboxylase inhibitor

1971 • 43 citations

?On-off? phenomenon in Parkinson's disease: Correlation to the concentration of dopa in plasma

1984 • 42 citations

Methyldopahydrazine as an adjunct to L‐dopa therapy in parkinsonism

1972 • 41 citations

Plasma levodopa, dopamine and therapeutic response following levodopa therapy of Parkinsonian patients

1980 • 41 citations

Modification of Levodopa Effect by Systemic Decarboxylase Inhibition

1973 • 41 citations

Physiologic disposition of pergolide

1981 • 40 citations

Comparative investigation of inhibitors of extracerebral dopa decarboxylase in man and rats

1972 • 40 citations

In-vitro decarboxylation of new phenylalanine derivatives

1964 • 40 citations

Amantadine hydrochloride pharmacokinetics in patients with impaired renal function.

1982 • 40 citations

ARTANE® THERAPY FOR PARKINSONISM

1949 • 40 citations

Metabolism of carbidopa (1-(-)-alpha-hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate), an aromatic amino acid decarboxylase inhibitor, in the rat, rhesus monkey, and man.

1974 • 40 citations

Acute Toxic Psychosis From Suicidal Overdosage of Amantadine

1971 • 39 citations

Amantadine-dyazide interaction.

1983 • 39 citations

Pyridoxine Antagonism of Levodopa in Parkinsonism

1971 • 39 citations

Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa

1973 • 38 citations

Plasma Concentration of Levodopa in Patients with Parkinson’s Disease

1973 • 38 citations

Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate; effect on plasma prolactin level

1981 • 38 citations

Catecholamine Metabolism During Oral Administration of Levodopa

1972 • 36 citations

DOPA and amino acid levels in plasma and cerebrospinal fluid of patients with parkinson's disease before and during treatment with L-dOPA

1973 • 35 citations

l-3,4-dihydroxyphenylalanine metabolism by the GUT IN VITRO††Address reprint requests to: Dr.L. Rivera-Calimlim at Rochester University School of Medicine and Dentistry, Department of Pharmacology, Rochester, N.Y. 14620, U.S.A.

1971 • 35 citations

FIVE YEAR FOLLOW-UP OF TREATMENT WITH TRIHEXYPHENIDYL (ARTANE)

1954 • 35 citations

Dosage form design for improvement of bioavailability of levodopa IV: Possible causes of low bioavailability of oral levodopa in dogs

1981 • 35 citations

Peripheral Aromatic L-Amino Acids Decarboxylase Inhibitor in Parkinsonism. I. EFFECT ON O-METHYLATED METABOLITES OF L-DOPA-2-14C

1972 • 35 citations

Pharmacokinetics of trihexyphenidyl after short‐term and long‐term administration to dystonic patients

1985 • 35 citations

Pharmacokinetics and Clinical Effects of Amantadine in Drug‐Induced Extrapyramidal Symptoms

1977 • 34 citations

Delayed Onset of Responses to Single Doses of L-Dopa in Parkinsonian Fluctuators on Long-Term L-Dopa Therapy

1986 • 34 citations

Dosage form design for improvement of bioavailability of levodopa III: Influence of dose on pharmacokinetic behavior of levodopa in dogs and parkinsonian patients

1980 • 34 citations

L-Dopa Treatment in Parkinson’s Disease

1970 • 34 citations

Effect of Supplemental Carbidopa on Bioavailability of l-Dopa

1986 • 34 citations

Biperiden effects and plasma levels in volunteers

1984 • 33 citations

Determination of nanogram quantities of diphenhydramine and orphenadrine in human plasma using gas-liquid chromatography

1973 • 32 citations

Intestinal Decarboxylation of Orally Administered L‐dopa

1975 • 32 citations

Imipramine‐mediated interference with levodopa absorption from the gastrointestinal tract in man

1975 • 32 citations

Pharmacokinetic aspects of deprenyl effects.

1984 • 32 citations

Reversal by Levodopa of Cholinergic Hypersensitivity in Parkinson's Disease

1971 • 32 citations

Comparison of benefit from L-dopa in Parkinsonism with increase of amine metabolites in the CSF

1971 • 32 citations

Levodopa, Carbidopa, and Pyridoxine in Parkinson Disease

1974 • 31 citations

Blocking the Negative Effects of Pyridoxine on Patients Receiving Levodopa

1971 • 31 citations

Decrease of the 3,4-Dihydroxyphenylalanine (DOPA) Decarboxylase Activities in Human Erythrocytes and Mouse Tissues after Administration of DOPA

1971 • 31 citations

Diphenhydramine disposition in chronic liver disease

1984 • 30 citations

Dosage form Design for Improvement of Bioavailability of Levodopa V: Absorption and Metabolism of Levodopa in Intestinal Segments of Dogs

1981 • 30 citations

USE OF LEVODOPA WITH OTHER DRUGS

1970 • 29 citations

Pathophysiology of L-Dopa-Induced Abnormal Involuntary Movements

1985 • 29 citations

Biochemical investigations in patients with Parkinson's disease treated with L‐dopa

1972 • 28 citations

Absorption of levodopa after rectal administration

1981 • 28 citations

3-O-Methyldopa, L-dopa, and trihexyphenidyl in the treatment of Parkinson's disease.

1973 • 28 citations

Increased Ratio of Carbidopa to Levodopa in Treatment of Parkinson's Disease

1980 • 28 citations

ABNORMAL INVOLUNTARY MOVEMENTS IN RELATION TO ANTICHOLINERGICS AND LEVODOPA THERAPY

1975 • 27 citations

Pharmacokinetics of bromocriptine during continuous oral treatment of Parkinson's disease

1979 • 27 citations

A double‐blind comparison of levodopa, madopa, and sinemet in Parkinson disease

1978 • 26 citations

Simultaneous determination of levodopa, its metabolites and carbidopa in clinical samples

1987 • 26 citations

The pharmacokinetics and biotransformation of14C-Lisuride hydrogen maleate in rhesus monkey and in man

1984 • 25 citations

Plasma bromocriptine levels, clinical and growth hormone responses in Parkinsonism.

1978 • 25 citations

AMANTADINE VERSUS L-DOPA AND AMANTADINE PLUS L-DOPA

1970 • 25 citations

The Effect of Antacid Administration on the Absorption and Metabolism of Levodopa

1972 • 25 citations

Peripheral aromatic <scp>l</scp>‐amino acids decarboxylase inhibitor in parkinsonism. II. Effect on metabolism of <scp>l</scp>‐2‐¹⁴C‐dopa

1972 • 24 citations

L‐dopa decarboxylation in chronically treated patients

1984 • 24 citations

PLASMA DOPA CONCENTRATIONS AFTER DIFFERENT PREPARATIONS OF LEVODOPA IN NORMAL SUBJECTS

1976 • 23 citations

Kemadrin in the Treatment of Parkinsonism

1955 • 23 citations

THE ABSORPTION AND METABOLISM OF A STANDARD ORAL DOSE OF LEVODOPA IN PATIENTS WITH PARKINSONISM

1974 • 23 citations

Sixteen-year follow-up of 100 patients begun on levodopa in 1968: emerging problems.

1987 • 23 citations

Diphenhydramine Determination in Human Plasma by Gas–Liquid Chromatography using Nitrogen–Phosphorus Detection: Application to Single Low-Dose Pharmacokinetic Studies

1983 • 23 citations

Acid Monoamine Metabolites in the Cerebrospinal Fluid of Parkinsonian Patients Treated with Levodopa alone or Combined with a Decarboxylase Inhibitor

1973 • 22 citations

["Beginning and end of dose" dyskinesias caused by L-DOPA].

1977 • 21 citations

Decarboxylation of orally administered l-dopa in the human digestive tract

1972 • 21 citations

Secretion of the gastrokinetic agent cisapride in human milk

1986 • 21 citations

Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease.

1972 • 21 citations

Metabolism of orphenadrine citrate in man.

1971 • 21 citations

Failure of cerebrospinal fluid homovanillic acid to predict levodopa response in Parkinson's disease

1973 • 20 citations

Increased Dosage of Carbidopa in Patients With Parkinson's Disease Receiving Low Doses of Levodopa

1980 • 19 citations

Serum trihexyphenidyl levels in the treatment of torsion dystonia

1985 • 19 citations

Severity of Parkinson's disease and the dosage of bromocriptine

1984 • 18 citations

Plasma concentrations of L-dopa and 3-methoxydopa and improvement in clinical ratings and motor performance in patients with Parkinsonism treated with L-dopa alone or in combination with amantadine.

1975 • 18 citations

Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease

1978 • 18 citations

Intestinal decarboxylation of L-Dopa in relation to dose requirement in Parkinson's disease

1973 • 17 citations

Pharmacokinetic and metabolic studies of the decarboxylase inhibitor benserazide in animals and man.

1978 • 17 citations

Analysis of procyclidine in human plasma and urine by gas—liquid chromatography

1980 • 16 citations

Selective inhibition of the "B form" of monoamine oxidase.

1977 • 16 citations

SUSTAINED-RELEASE LEVODOPA IN PARKINSONISM

1973 • 15 citations

Dose regimen of deprenyl (selegiline) and platelet MAO activities

1983 • 15 citations

SUSTAINED-RELEASE LEVODOPA IN PARKINSONISM

1973 • 15 citations

Quantitative Evaluation of the Blood‐Brain Barrier Capacity to Form Dopamine from Circulating L‐DOPA

1977 • 15 citations

In Vitro Binding of Amantadine to Plasma Proteins

1984 • 15 citations

BROMOCRIPTINE AND DOPAMINE RECEPTOR STIMULATION

1976 • 14 citations

Pharmacokinetics of the decarboxylase inhibitor benserazide in man; its tissue distribution in the rat

1974 • 14 citations

A REVIEW OF DRUG THERAPY IN PARKINSONISM.

1965 • 14 citations

Disposition of oral lisuride in parkinson's disease

1984 • 13 citations

The pharmacokinetics of lisuride hydrogen maleate in rat, rabbit and rhesus monkey

1981 • 13 citations

The role of the liver in the clearance ofl-dopa from plasma

1975 • 13 citations

Experimental Preparation W-483 in the Treatment of Parkinson's Disease

1952 • 13 citations

Treatment of advanced Parkinson's disease with dopamine agonists

1981 • 13 citations

[Abnormal movements caused by L-DOPA in patients with Parkinson's disease: correlation with the plasma concentrations of DOPA and O-methyl-DOPA].

1977 • 12 citations

Metabolism and Urinary Excretion of Benzhexol in Humans

1978 • 12 citations

Determination of biperiden in human serum by glass capillary gas chromatography with isothermal splitless injection and nitrogen-sensitive detection

1981 • 12 citations

Effect of gastric motility on levodopa.

1972 • 12 citations

Effect of Pyridoxine on Levodopa Metabolism in Normal and Parkinsonian Subjects

1973 • 11 citations

Effect of a slow release preparation of levodopa on Parkinson's disease in combination with a peripheral decarboxylase inhibitor

2009 • 11 citations

SLOWLY ABSORBED L-DOPA PREPARATION IN THE TREATMENT OF PARKINSONISM

2009 • 11 citations

Preliminary study of a new anti-parkinson agent.

1952 • 11 citations

KEMADRIN IN THE TREATMENT OF PARKINSONISM: A DOUBLE BLIND AND ONE-YEAR FOLLOW-UP STUDY.

1965 • 10 citations

Effect of chronic drug treatment on intestinal membrane transport of ¹⁴C‐<scp>l</scp>‐DOPA

1972 • 10 citations

Plasma DOPA and growth hormone in parkinsonism

1979 • 10 citations

Role of B-Type Monoamine Oxidase Inhibition in the Treatment of Parkinson’s Disease

1986 • 9 citations

Pergolide treatment in parkinsonism.

1983 • 8 citations

Enhancement of the pharmacological action of 3,4-dihydroxy-L-phenylalanine (L-DOPA) and reduction of DOPA decarboxylase activity in rat liver after chronic treatment with L-DOPA

1973 • 8 citations

Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies.

1983 • 7 citations

[Metabolism of antiparkinson drugs. An example of competitive hydroxylation].

1979 • 7 citations

The comparative value of amantadine and levodopa

1972 • 6 citations

Blood‐brain barrier permeability of L‐dopa in man

1981 • 5 citations

Metabolic studies of 3 H-orphenadrine citrate in the rat, dog and rhesus monkey.

1972 • 5 citations

Bromocriptine

1979 • 4 citations

Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa

1983 • 4 citations

Effect of carbidopa on the metabolism of l-dopa in the pigtail monkey

1976 • 4 citations

THE EFFECT OF A SLOW RELEASE PREPARATION OF LEVODOPA ON PARKINSONISM IN COMBINATION WITH A PERIPHERAL DOPA DECARBOXYLASE INHIBITOR

1978 • 2 citations

Deleted Work

1955 • 0 citations